Pentostatin (Nipent®) in the treatment of chronic lymphocyte leukemia and hairy cell leukemia

Expert Review of Anticancer Therapy

Volumn 4, Issue 1, 2004, Pages 27-36

  Dillman, Robert O ^a  

^a HOAG MEMORIAL HOSPITAL PRESBYTERIAN   (United States)

Author keywords

Chronic lymphocyte leukemia; Deoxycoformycin; Hairy cell leukemia; Nucleoside analogs; Pentostatin; Purine analogs

Indexed keywords

4 HYDROPEROXYCYCLOPHOSPHAMIDE; ADENOSINE; ADENOSINE DEAMINASE; ALKYLATING AGENT; ALPHA INTERFERON; ALPHA2A INTERFERON; ANTINEOPLASTIC AGENT; CHLORAMBUCIL; CLADRIBINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEOXYADENOSINE; FLUDARABINE PHOSPHATE; GRANULOCYTE COLONY STIMULATING FACTOR; LEUSTAT; MONOCLONAL ANTIBODY; PENTOSTATIN; PREDNISONE; PURINE DERIVATIVE; RIBONUCLEOTIDE REDUCTASE; RITUXIMAB; ANTINEOPLASTIC ANTIBIOTIC; ENZYME INHIBITOR;

ANEMIA; ARTICLE; BACTERIAL INFECTION; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; DISEASE EXACERBATION; DNA SYNTHESIS INHIBITION; DRUG APPROVAL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG RESPONSE; DRUG STRUCTURE; ENZYME INHIBITION; FOOD AND DRUG ADMINISTRATION; HAIRY CELL LEUKEMIA; HEPATITIS; HUMAN; IMMUNE DEFICIENCY; KERATOCONJUNCTIVITIS; KIDNEY FAILURE; LETHARGY; LUNG TOXICITY; LYMPHOCYTOPENIA; METABOLITE; MONOTHERAPY; MYELODYSPLASIA; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OPPORTUNISTIC INFECTION; PNEUMONIA; RASH; SEPSIS; SOMNOLENCE; SURVIVAL RATE; THROMBOCYTOPENIA; UNITED STATES; REVIEW;

ANTIBIOTICS, ANTINEOPLASTIC; CLINICAL TRIALS; ENZYME INHIBITORS; HUMANS; LEUKEMIA, HAIRY CELL; LEUKEMIA, LYMPHOCYTIC, CHRONIC; PENTOSTATIN;

EID: 85047691474     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.4.1.27     Document Type: Article

References (61)

1. Polliack A. Hairy cell leukemia: biology, clinical diagnosis, unusual manifestations and associated disorders. Rev. Clin. Exp. Hematol. 6, 366-388 (2002).
2. Tallman MS. Current treatment strategies for patients with hairy cell leukemia. Rev. Clin. Exp. Hematol. 6, 389-400 (2002).
3. Saven A, Burian C, Koziol JA, Piro LD. Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood 92, 1918-1926 (1998).
4. Kay NE, Hamblin TJ, Jelinick EF et al. Chronic lymphocyte leukemia. Hematology (Am. Soc. Hematol. Educ. Program) 193-213 (2002).
5. Keating MJ. Management of chronic lymphocyte leukemia: a changing field. Rev. Clin. Exp. Hematol. 6, 350-365 (2002).
6. Keating MJ, O'Brien S, Lerner S et al. Long-term follow-up of patients with chronic lymphocyte leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood 92, 1165-1171 (1998).
7. Rai KR, Peterson BL, Appelbaum FR et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocyte leukemia. N. Engl. J. Med. 343, 1750-1757 (2000).
8. Cheson BD. The purine analogs: a therapeutic beauty contest. J. Clin. Oncol. 10, 352-355 (1992).
9. Johnson SA, Thomas W. Therapeutic potential of purine analog combinations in the treatment of lymphoid malignancies. Hematol. Oncol. 18, 141-153 (2000).
10. Tallman MS, Hakimian D. Purine nucleoside analogs: emerging roles in indolent lymphoproliferative disorders. Blood 86, 2463-2472 (1995).
11. O'Dwyer PJ, Wagner B, Leyland-Jones B et al. 2′-Deoxycoformycin (pentostatin) for lymphoid malignancies. Rational development of an active new drug. Ann. Intern. Med. 108, 733-743 (1988).
12. Kane BJ, Kuhn JG, Roush MK. Pentostatin: an adenosine deaminase inhibitor for the treatment of hairy cell leukemia. Ann. Pharmcother. 26, 939-947 (1992).
13. Cummings FJ, Crabtree GW, Wiemann MC, Spremulli EN, Parks RE Jr, Calabresi P. Clinical, pharmacologic and immunologic effects of 2′-deoxycoformycin. Clin. Pharmacol. Ther. 44, 501-509 (1988).
14. Smyth JF, Paine RM, Jackman Al et al. The clinical pharmacology of the adenosine deaminase inhibitor 2′-deoxycoformycin. Cancer Chemother. Pharmacol. 5, 93-101 (1980).
15. Major PP, Agarwal RP, Kufe DW. Clinical pharmacology of deoxycoformycin. Blood 58, 91-96 (1981).
16. Kanofsky JR, Roth DG, Smyth JF, Baron JM, Sweet DL, Ultmann JE. Treatment of lymphoid malignancies with 2′ deoxycoformycin. A pilot study. Am. J. Clin. Oncol. 5, 179-183 (1982).
17. Grever MR, Coleman MS, Gray DP, Malspeis L, Balcerzak SP. Definition of safe, effective dosing regimen of 2′ deoxycoformycin with biochemical investigation. Cancer Treat. Symp. 2, 43-49 (1984).
18. Grever MR, Leiby JM, Kraut EH et al. Low-dose deoxycoformycin in lymphoid malignancy. J. Clin. Oncol. 3, 1196-1201 (1985).
19. Spiers AS, Parekh SJ, Bishop MB. Hairy-cell leukemia: induction of complete remission with pentostatin (2′ deoxycoformycin). J. Clin. Oncol. 2, 1336-1342 (1984).
20. Foon KA, Nakano GM, Koller CA, Longo DL, Steis RG. Response to 2′ deoxycoformycin after failure of interferon-α in nonsplenectomized patients with hairy cell leukemia. Blood 68, 297-300 (1986).
21. Ho AD, Kuse R, Prummer O, Porzsolt F, Hunstein W. 2′ Deoxycoformycin (pentostatin) in hairy cell leukemia: response in patients refractory to interferon-α. Klin. Wochenschr. 65, 975-979 (1987).
22. Johnston JB, Glazer RI, Pugh L, Israels LG. The treatment of hairy-cell leukaemia with 2′ deoxycoformycin. Br. J. Haematol. 63, 525-534 (1986).
23. Kraut EH, Bouroncle BA, Grever MR. Low-dose deoxycoformycin in the treatment of hairy cell leukemia. Blood 68, 1119-1122 (1986).
24. Dalal BI, Freier L, Johnston JB, Merry CC, Israels LG. Peripheral blood and bone marrow changes following 2′ deoxycoformycin therapy in hairy cell leukemia. Results of 200 weeks follow-up. Cancer 63, 14-22 (1989).
25. Spiers AS, Moore D, Cassileth PA et al. Remission in hairy-cell leukemia with pentostatin (2′ deoxycoformycin). N. Engl. J. Med. 316, 825-830 (1987).
26. Cassileth PA , Cheuvart B, Spiers AS et al. Pentostatin induces durable remissions in hairy cell leukemia. J. Clin. Oncol. 9, 243-246 (1991).
27. Johnston JB, Eisenhauer E, Corbett WE, Scott JG, Zaentz SD. Efficacy of 2′ deoxycoformycin in hairy-cell leukemia: a study of the National Cancer Institute of Canada Clinical Trials Group. J. Natl Cancer Inst. 80, 765-769 (1988).
28. Blick M, Lepe-Zuniga JL, Doig R, Quesada JR. Durable complete remissions after 2′ deoxycoformycin treatment in patients with hairy cell leukemia resistant to interferon-α. Am. J. Hematol. 33, 205-209 (1990).
29. Annino L, Ferrari A, Giona F et al. Deoxycoformycin induces long-lasting remissions in hairy cell leukemia: clinical and biological results of two different regimens. Leuk. Lymphoma 14(Suppl. 1), 115-119 (1994).
30. Ho AD, Thaler J, Mandelli F et al. Response to pentostatin in hairy-cell leukemia refractory to interferon-α. The European Organization for Research and Treatment of Cancer Leukemia Co-operative Group. J. Clin. Oncol. 7, 1533-1538 (1989).
31. Martin A, Nerenstone S, Urba WJ et al. Treatment of hairy cell leukemia with alternating cycles of pentostatin and recombinant leukocyte A interferon: results of a Phase II study. J. Clin. Oncol. 8, 721-730 (1990).
32. 2a previously untreated patients with hair cell leukemia: an intergroup study. J. Clin. Oncol. 13, 974-982 (1995).
33. Kraut EH, Grever MR, Bouroncle BA. Long-term follow-up of patients with hairy cell leukemia after treatment with 2′ deoxycoformycin. Blood 84, 4061-4063 (1994).
34. Ribeiro P, Bouaffia F, Peaud PY et al. Long-term outcome of patients with hairy cell leukemia treated with pentostatin. Cancer 85, 65-71 (1999).
35. Johnston JB, Eisenhauer E, Wainman N, Corbett WE, Zaentz SD, Daeninck PJ. Long-term outcome following treatment of hairy cell leukemia with pentostatin (Nipent): a National Cancer Institute of Canada study. Semin. J. Oncol. 27(2 Suppl. 5), 32-36 (2000).
36. Maloisel F, Benboubker L, Gardembas M et al. Long-term outcome with pentostatin treatment in hairy cell leukemia patients. A French retrospective study of 238 patients. Leukemia 17, 45-52 (2003).
37. Dearden CE, Matutes E, Hilditch BL, Swansbury GJ, Catovsky D. Long-term follow-up of patients with hairy cell leukemia after treatment with pentostatin or cladribine. Br. J. Haematol. 106, 515-519 (1999).
38. Flinn IW, Kopecky KJ, Foucar MK et al. Long-term follow-up of remission duration, mortality and second malignancies in hairy cell leukemia patients treated with pentostatin. Blood 96, 2981-2986 (2000).
39. Margolis J, Grever MR. Pentostatin (Nipent): a review of potential toxicity and its management. Semin. Oncol. 27, 9-14 (2000).
40. Grever MR, Siaw MP, Jacob WF et al. The biochemical and clinical consequences of 2′-deoxycoformycin in refractory lymphoproliferative malignancy. Blood 57, 406-417 (1981).
41. Dillman RO, Yu AL, Qiao C-N. Repeated pentostatin (2′ deoxycoformycin) induced remissions in a patient with advanced chronic lymphocyte leukemia. West J. Med. 148, 334-339 (1988).
42. Dillman RO, Mick R, McIntyre OR. Pentostatin in chronic lymphocyte leukemia: a Phase II trial of Cancer and Leukemia Group B. J. Clin. Oncol. 7, 433-438 (1989).
43. Ho AD, Thaler I, Stryekmans F et al. Pentostatin in refractory chronic lymphocyte leukemia: a Phase II trial of the European Organization for Research and Treatment of Cancer. J. Natl Cancer Inst. 82, 1416-1420 (1990).
44. Johnson SA, Catovsky D, Child JA, Newland AC, Milligan DW, Janmohamed R. Phase I/II evaluation of pentostatin (2′-deoxycoformycin) in a five day schedule for the treatment of relapsed/refractory B-cell chronic lymphocyte leukaemia. Invest. New Drugs 16, 155-160 (1998).
45. Dearden CE, Matutes E, Catovsky D. Clinical overview of pentostatin (Nipent) use in lymphoid malignancies. Semin. Oncol. 27(2 Suppl. 5), 22-26 (2000).
46. Morrison VA, Rai KR, Peterson BL et al. Therapy-related myeloid leukemias are observed in patients with chronic lymphocyte leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, Cancer and Leukemia Group B 9011. J. Clin. Oncol. 20, 3878-3884 (2002).
47. Weiss MA, Glenn M, Maslak P et al. Consolidation therapy with high-dose cyclophosphamide improves the quality of response in patients with chronic lymphocyte leukemia treated with fludarabine as induction therapy. Leukemia 14, 577-1582 (2000).
48. Flinn IW, Byrd JC, Morrison C et al. Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies. Blood 96, 71-75 (2000).
49. O'Brien SM, Kantarjian HM, Cortes J et al. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocyte leukemia. J. Clin. Oncol. 19, 1414-1420 (2001).
50. Keating MJ, Manshouri T, O'Brien S et al. A high proportion of true complete remission can be obtained with a fludarabine, cyclophosphamide, rituximab combination (FCR) in chronic lymphocyte leukemia. Proc. Am. Soc. Clin. Oncol. 22 (2003) (Abstract 2289).
51. Ketterer N, Salles G, Moullet I et al. Factors associated with successful mobilization of peripheral blood progenitor cells in 200 patients with lymphoid malignancies. Br. J. Haematol. 103, 235-242 (1998).
52. Johnston JB, Verburg L, Shore T, Williams M, Israels LG, Begleiter A. Combination therapy with nucleoside analogs and alkylating agents. Leukemia 8(Suppl. 1), S140-S143 (1994).
53. Oken MM, Lee S, Cassileth PA, Krigel RI. Pentostatin, chlorambucil and prednisone for the treatment of chronic lymphocyte leukemia: Eastern Co-operative Oncology Group Protocol E1488. Proc. Am. Assoc. Clin. Oncol. 17, 6a (1998) (Abstract 22).
54. Waselenko JK, Grever MR, Beer M, Lucas MA, Byrd JC. Pentostatin (Nipent) and chlorambucil with granulocyte-macrophage colony-stimulating factor support for patients with previously untreated, treated and fludarabine-refractory B-cell chronic lymphocyte leukemia. Semin. Oncol. 27(2 Suppl. 5), 44-51 (2000).
55. Weiss MA, Maslak PG, Juric JG et al. Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocyte leukemia. J. Clin. Oncol. 21, 1278-1284 (2003).
56. Tefferi A, Levitt R, Li CY et al. Phase II study of 2-chlorodeoxyadenosine in combination with chlorambucil in previously untreated B-cell chronic lymphocyte leukemia. Am. J. Clin. Oncol. 22, 509-516 (1999).
57. Montillo M, Tedeschi A, O'Brien S et al. Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocyte leukemia and prolymphocytic leukemia. Cancer 97, 114-120 (2003).
58. Dillman RO. New chemotherapeutic agent: deoxycoformycin (pentostatin). Semin. Hematol. 31, 16-27 (1994).
59. Kraut EH, Neff JC, Bouroncle BA, Gochnour D, Grever MR. Immunosuppressive effects of pentostatin. J. Clin. Oncol. 8, 848-855 (1990).
60. Cheson BD, Vena DA, Barrett J, Freidlin B. Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias. J. Clin. Oncol. 17, 2454-2460 (1999).
61. Goodman GR, Burian C, Koziol JA, Saven A. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. J. Clin. Oncol. 21, 891-896 (2003).